2-165090746-C-T
Variant summary
Our verdict is Benign. The variant received -7 ACMG points: 2P and 9B. PM1BP4BA1
This summary comes from the ClinGen Evidence Repository: The c.5407G>A variant in SCN3A is a missense variant predicted to cause substitution of Aspartic acid by Asparagine at amino acid 1803 (p.Asp1803Asn). The highest population minor allele frequency in gnomAD v2.1.1 is 0.01653 (143/8652 alleles) in East Asian population, which is higher than the ClinGen Epilepsy Sodium Channel threshold (0.0001) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.114, which is below the threshold of 0.183, evidence that does not predict a damaging effect on SCN3A function (BP4_moderate). This variant resides within a region of SCN3A that is defined as a mutational hotspot by the ClinGen sodium channel VCEP (PM1). Although there are both pathogenic and benign types of evidence for this variant, the high frequency of this variant in gnomAD strongly supports a benign classification, and the only evidence in support of pathogenicity is based on a prediction that this variant may lie in a mutational hotspot. In summary, this variant meets the criteria to be classified as Benign for autosomal dominant developmental and epileptic encephalopathy based on ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: BA1, BP4, and PM1. (VCEP specifications version 1; 6/27/2023). LINK:https://erepo.genome.network/evrepo/ui/classification/CA1938411/MONDO:0100062/069
Frequency
Consequence
NM_006922.4 missense
Scores
Clinical Significance
Conservation
Publications
- genetic developmental and epileptic encephalopathyInheritance: AD Classification: DEFINITIVE Submitted by: Illumina, ClinGen
- developmental and epileptic encephalopathy, 62Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- epilepsy, familial focal, with variable foci 4Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- undetermined early-onset epileptic encephalopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000612 AC: 93AN: 152076Hom.: 3 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00137 AC: 344AN: 251408 AF XY: 0.00128 show subpopulations
GnomAD4 exome AF: 0.000544 AC: 795AN: 1461846Hom.: 5 Cov.: 32 AF XY: 0.000547 AC XY: 398AN XY: 727226 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000611 AC: 93AN: 152194Hom.: 3 Cov.: 32 AF XY: 0.000578 AC XY: 43AN XY: 74398 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Developmental and epileptic encephalopathy Benign:1
The c.5407G>A variant in SCN3A is a missense variant predicted to cause substitution of Aspartic acid by Asparagine at amino acid 1803 (p.Asp1803Asn). The highest population minor allele frequency in gnomAD v2.1.1 is 0.01653 (143/8652 alleles) in East Asian population, which is higher than the ClinGen Epilepsy Sodium Channel threshold (0.0001) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.114, which is below the threshold of 0.183, evidence that does not predict a damaging effect on SCN3A function (BP4_moderate). This variant resides within a region of SCN3A that is defined as a mutational hotspot by the ClinGen sodium channel VCEP (PM1). Although there are both pathogenic and benign types of evidence for this variant, the high frequency of this variant in gnomAD strongly supports a benign classification, and the only evidence in support of pathogenicity is based on a prediction that this variant may lie in a mutational hotspot. In summary, this variant meets the criteria to be classified as Benign for autosomal dominant developmental and epileptic encephalopathy based on ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: BA1, BP4, and PM1. (VCEP specifications version 1; 6/27/2023). -
not provided Benign:1
- -
SCN3A-related disorder Benign:1
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at